Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 913.00 Cr.. The value appears strong and on an upward trend. It has increased from 462.00 Cr. (Dec 2024) to 913.00 Cr., marking an increase of 451.00 Cr..
For Expenses, as of Mar 2025, the value is 723.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 447.00 Cr. (Dec 2024) to 723.00 Cr., marking an increase of 276.00 Cr..
For Operating Profit, as of Mar 2025, the value is 190.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Dec 2024) to 190.00 Cr., marking an increase of 175.00 Cr..
For OPM %, as of Mar 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 3.00% (Dec 2024) to 21.00%, marking an increase of 18.00%.
For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Dec 2024) to 1.00 Cr., marking a decrease of 3.00 Cr..
For Interest, as of Mar 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Dec 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 13.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Dec 2024) to 13.00 Cr., marking an increase of 8.00 Cr..
For Profit before tax, as of Mar 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Dec 2024) to 173.00 Cr., marking an increase of 163.00 Cr..
For Tax %, as of Mar 2025, the value is 1.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Dec 2024) to 1.00%, marking a decrease of 36.00%.
For Net Profit, as of Mar 2025, the value is 172.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Dec 2024) to 172.00 Cr., marking an increase of 166.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 27.01. The value appears strong and on an upward trend. It has increased from 1.01 (Dec 2024) to 27.01, marking an increase of 26.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: March 7, 2025, 9:26 pm
Metric
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
TTM
Sales
388
404
431
397
431
513
843
1,767
1,867
2,009
2,255
2,328
2,578
Expenses
291
319
331
305
331
387
658
1,446
1,522
1,664
1,918
2,020
2,226
Operating Profit
97
85
100
91
99
125
185
321
344
345
337
308
352
OPM %
25%
21%
23%
23%
23%
24%
22%
18%
18%
17%
15%
13%
14%
Other Income
16
19
28
32
32
35
28
-33
-123
10
-5
-0
23
Interest
0
0
0
0
1
2
30
140
84
26
16
24
14
Depreciation
4
0
8
7
7
9
13
26
25
24
25
24
21
Profit before tax
108
104
120
117
124
150
171
121
112
306
291
260
340
Tax %
8%
5%
7%
10%
10%
9%
-0%
-17%
-6%
-1%
-7%
-3%
Net Profit
99
98
111
105
111
137
171
142
119
309
310
267
325
EPS in Rs
24.85
24.69
27.88
26.43
27.89
34.27
29.33
24.58
18.66
48.54
48.78
41.94
51.12
Dividend Payout %
24%
24%
22%
25%
23%
23%
17%
20%
27%
10%
10%
12%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2013-2014
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
YoY Net Profit Growth (%)
-1.01%
13.27%
-5.41%
5.71%
23.42%
24.82%
-16.96%
-16.20%
159.66%
0.32%
-13.87%
Change in YoY Net Profit Growth (%)
0.00%
14.28%
-18.67%
11.12%
17.71%
1.39%
-41.78%
0.76%
175.86%
-159.34%
-14.19%
Zydus Wellness Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth
10 Years:
20%
5 Years:
9%
3 Years:
10%
TTM:
16%
Compounded Profit Growth
10 Years:
12%
5 Years:
14%
3 Years:
3%
TTM:
22%
Stock Price CAGR
10 Years:
8%
5 Years:
9%
3 Years:
6%
1 Year:
3%
Return on Equity
10 Years:
7%
5 Years:
6%
3 Years:
6%
Last Year:
6%
Last Updated: Unknown
No data available for the Balance Sheet data table.
After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 41.94. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.94, marking a decrease of 6.84.
For Diluted EPS (Rs.), as of Mar 24, the value is 41.94. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.94, marking a decrease of 6.84.
For Cash EPS (Rs.), as of Mar 24, the value is 45.71. This value is within the healthy range. It has decreased from 52.71 (Mar 23) to 45.71, marking a decrease of 7.00.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 842.37. It has increased from 805.07 (Mar 23) to 842.37, marking an increase of 37.30.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 842.37. It has increased from 805.07 (Mar 23) to 842.37, marking an increase of 37.30.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 366.01. It has increased from 354.36 (Mar 23) to 366.01, marking an increase of 11.65.
For PBDIT / Share (Rs.), as of Mar 24, the value is 50.64. This value is within the healthy range. It has decreased from 53.75 (Mar 23) to 50.64, marking a decrease of 3.11.
For PBIT / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 49.82 (Mar 23) to 46.90, marking a decrease of 2.92.
For PBT / Share (Rs.), as of Mar 24, the value is 40.90. This value is within the healthy range. It has decreased from 45.71 (Mar 23) to 40.90, marking a decrease of 4.81.
For Net Profit / Share (Rs.), as of Mar 24, the value is 41.97. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.97, marking a decrease of 6.81.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 41.97. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.97, marking a decrease of 6.81.
For PBDIT Margin (%), as of Mar 24, the value is 13.83. This value is within the healthy range. It has decreased from 15.16 (Mar 23) to 13.83, marking a decrease of 1.33.
For PBIT Margin (%), as of Mar 24, the value is 12.81. This value is within the healthy range. It has decreased from 14.05 (Mar 23) to 12.81, marking a decrease of 1.24.
For PBT Margin (%), as of Mar 24, the value is 11.17. This value is within the healthy range. It has decreased from 12.89 (Mar 23) to 11.17, marking a decrease of 1.72.
For Net Profit Margin (%), as of Mar 24, the value is 11.46. This value exceeds the healthy maximum of 10. It has decreased from 13.76 (Mar 23) to 11.46, marking a decrease of 2.30.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 11.46. This value is within the healthy range. It has decreased from 13.76 (Mar 23) to 11.46, marking a decrease of 2.30.
For Return on Networth / Equity (%), as of Mar 24, the value is 4.98. This value is below the healthy minimum of 15. It has decreased from 6.05 (Mar 23) to 4.98, marking a decrease of 1.07.
For Return on Capital Employeed (%), as of Mar 24, the value is 5.54. This value is below the healthy minimum of 10. It has decreased from 6.16 (Mar 23) to 5.54, marking a decrease of 0.62.
For Return On Assets (%), as of Mar 24, the value is 4.34. This value is below the healthy minimum of 5. It has decreased from 5.32 (Mar 23) to 4.34, marking a decrease of 0.98.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.38. It has increased from 0.05 (Mar 23) to 0.38, marking an increase of 0.33.
For Current Ratio (X), as of Mar 24, the value is 1.62. This value is within the healthy range. It has increased from 1.31 (Mar 23) to 1.62, marking an increase of 0.31.
For Quick Ratio (X), as of Mar 24, the value is 1.02. This value is within the healthy range. It has increased from 0.65 (Mar 23) to 1.02, marking an increase of 0.37.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.24. This value is below the healthy minimum of 4. It has increased from 0.89 (Mar 23) to 2.24, marking an increase of 1.35.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 11.91. This value is below the healthy minimum of 20. It has increased from 10.25 (Mar 23) to 11.91, marking an increase of 1.66.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 10.93. This value is below the healthy minimum of 20. It has increased from 9.48 (Mar 23) to 10.93, marking an increase of 1.45.
For Earning Retention Ratio (%), as of Mar 24, the value is 88.09. This value exceeds the healthy maximum of 70. It has decreased from 89.75 (Mar 23) to 88.09, marking a decrease of 1.66.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 89.07. This value exceeds the healthy maximum of 70. It has decreased from 90.52 (Mar 23) to 89.07, marking a decrease of 1.45.
For Interest Coverage Ratio (X), as of Mar 24, the value is 13.42. This value is within the healthy range. It has decreased from 21.27 (Mar 23) to 13.42, marking a decrease of 7.85.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 12.71. This value is within the healthy range. It has decreased from 20.93 (Mar 23) to 12.71, marking a decrease of 8.22.
For Enterprise Value (Cr.), as of Mar 24, the value is 9,439.42. It has decreased from 10,116.33 (Mar 23) to 9,439.42, marking a decrease of 676.91.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.05. This value exceeds the healthy maximum of 3. It has decreased from 4.49 (Mar 23) to 4.05, marking a decrease of 0.44.
For EV / EBITDA (X), as of Mar 24, the value is 29.31. This value exceeds the healthy maximum of 15. It has decreased from 29.58 (Mar 23) to 29.31, marking a decrease of 0.27.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.02. This value exceeds the healthy maximum of 3. It has decreased from 4.37 (Mar 23) to 4.02, marking a decrease of 0.35.
For Retention Ratios (%), as of Mar 24, the value is 88.08. This value exceeds the healthy maximum of 70. It has decreased from 89.74 (Mar 23) to 88.08, marking a decrease of 1.66.
For Price / BV (X), as of Mar 24, the value is 1.75. This value is within the healthy range. It has decreased from 1.93 (Mar 23) to 1.75, marking a decrease of 0.18.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.02. This value exceeds the healthy maximum of 3. It has decreased from 4.37 (Mar 23) to 4.02, marking a decrease of 0.35.
For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Zydus Wellness Ltd as of June 13, 2025 is: 1,580.05
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 13, 2025, Zydus Wellness Ltd is Overvalued by 17.40% compared to the current share price 1,913.00
Intrinsic Value of Zydus Wellness Ltd as of June 13, 2025 is: 1,932.89
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 13, 2025, Zydus Wellness Ltd is Undervalued by 1.04% compared to the current share price 1,913.00
Last 5 Year EPS CAGR: 22.33%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zydus Wellness Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 4.98% (Industry Average ROE: 17.15%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 35.7 (Industry average Stock P/E: 165.31)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.06
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Zydus Wellness Ltd. is a Public Limited Listed company incorporated on 01/11/1994 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L15201GJ1994PLC023490 and registration number is 023490. Currently Company is involved in the business activities of Manufacture of other dairy products. Company's Total Operating Revenue is Rs. 292.60 Cr. and Equity Capital is Rs. 63.60 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Zydus Wellness Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
